75N91020F00009↗

Name: 75N91020F00009: On Behalf of Niaid-Dcr, Facilitate the Conduct of Two, Randomized Trials As Detailed Below in I and II: I. a Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of Covid-19 (2,000 Subjects
Creator: SpendQuery

ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II: I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS

Delivery Order · National Institutes of Health · to Leidos Biomedical Research Inc (UEI HV8BH9BPG8Y9) · data as of 2026-09-30

Obligated to date$19.67M6 actions

Current value$89.56Mwith options exercised

Potential value$136.72Mif every option is used

Period2020-04-01 → 2028-07-31current end date

Up for re-bid: ends 2028-07-31. Recompete brief →

What it is

Product or service: Health R&D Services; Health Care Services; Applied Research (PSC AN12)
Industry: Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) (NAICS 541715)
Contracting office: Nih Nci (75N910)
Competition: Full and open competition
Pricing: Cost plus fixed fee
How it was bought: Single-award IDIQ · under 75N91019D00024
Where the work is: Frederick, MD · district MD-06
Funding law: COVID-19 laws
Topics: covid

Obligations by fiscal year

FY2024$13.72M

FY2025$5.95M

SpendQuery holds FY2023 on; earlier years are on USAspending.gov.

Subcontractors: where the money went next

No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.

Every action

6 actions since 2023-10-31. Each is a modification or amendment with the money it added or took back.

Date	Modification	Kind	Amount	What the agency wrote
2025-09-29	P00012	Administrative change	$5.95M	NIAID DCR COVID-19 TRIALS - COVID-19 - NCI FEDERALLY FUNDED RESEARCH AND DEVELOPMENT CENTER (FFRDC) CONTRACT
2025-04-24	P00011	Terminated for convenience	$0	EOI::IMPLEMENTING THE PRESIDENTS DEPARTMENT OF GOVERNMENT EFFICIENCY COST EFFICIENCY INITIATIVE (MARCH 19, 2025)::EOI
2024-09-25	P00010	Administrative change	$13.72M	ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II: I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS
2024-08-21	P00009	Administrative change	$0	ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II: I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS
2024-05-31	P00008	Administrative change	$0	ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II: I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS
2023-10-31	P00007	Administrative change	$0	ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II: I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19 (2,000 SUBJECTS

Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-09-30). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗